OPCs are plant antioxidants, taken mainly as grape seed and pine bark extracts, long used for circulation and healthy aging. Human evidence supports small but repeatable drops in blood pressure, better blood fats and blood sugar, and lower inflammation. Well tolerated; the main cautions are mild blood-thinning and product quality. Benefits on arteries, brain, and lifespan remain unproven. (Full Review)

Protocol

Grape Seed Extract

100–300 mg/day

Standardized to a high proanthocyanidin content (~95% OPCs)

Pine Bark Extract (Pycnogenol)

50–200 mg/day

Standardized extract, often split into two doses

Timing

With meals

Improves tolerability and absorption; splitting doses keeps metabolite levels steadier

Time to effect

Blood Pressure & Markers

4–12 weeks

Blood pressure and blood-fat/sugar changes with consistent use

Venous Symptoms

A few weeks

Relief of leg heaviness and swelling

Longevity Effects

Inferred, not felt

Based on markers and mechanism, not directly experienced

Benefits

High: Modest blood pressure reduction, improved blood lipids

Medium: Reduced oxidative stress and inflammation, improved glycemic control, endothelial and vascular function, relief of chronic venous insufficiency and edema

Low: Skin photoprotection and appearance, cognitive and cerebrovascular support, diabetic retinopathy and eye health

Speculative: Longevity and healthspan, cancer risk reduction

Contraindications

Bleeding disorders

Anticoagulant use

Within ~2 weeks of surgery

Peanut allergy

Pregnancy or breastfeeding

Clinically low blood pressure

Key Interactions

Anticoagulant and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin)

NSAIDs (ibuprofen, naproxen)

Antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, diuretics)

Blood-pressure-lowering and antiplatelet supplements (garlic, hibiscus, fish oil, ginkgo, nattokinase)

Iron supplements and iron-rich meals

Antidiabetic drugs

Risk & Side Effects

High: Mild gastrointestinal upset

Medium: Headache and dizziness, increased bleeding tendency

Low: Allergic reactions and adulteration risk, additive hypotension

Speculative: Drug-metabolism interactions, unknown long-term high-dose safety

Monitoring

Marker	Target	Why
Blood pressure	~110–120 / 70–80 mmHg	Primary reproducible OPC benefit
LDL cholesterol	< 100 mg/dL (lower if high cardiac risk)	Tracks lipid response
Triglycerides	< 100 mg/dL	Most responsive lipid to OPCs
HDL cholesterol	> 50 mg/dL (women), > 40 mg/dL (men)	Context for lipid profile
Fasting glucose	70–90 mg/dL	Detects glycemic benefit
HbA1c	< 5.4%	Longer-term glucose control
hs-CRP	< 1.0 mg/L	Tracks inflammation, a longevity-relevant marker
ALT / AST	ALT < 25 (men) / < 20 (women) U/L	Safety monitoring for long-term use

Cadence: Recheck relevant markers at ~8–12 weeks after starting, then every 6–12 months if continued

Qualitative Assessment

Leg heaviness, swelling, or visible spider veins (for venous-insufficiency users)
Energy levels and exercise recovery
Cognitive clarity and mental fatigue
Skin appearance and sun tolerance
Any easy bruising or bleeding (a safety signal, not a benefit)

OPCs for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment